Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, Olivia Rastoin, Rosie Dawaliby, Thomas Schmitt, Maxence Bourgoin, Héliciane Palenzuela, Anne-Laure Rossi, Damien Ambrosetti, Jerome Durivault, Frederic Luciano, Delphine Borchiellini, Julie Le Du, Leticia Christina Pires Gonçalves, Patrick Auberger, Rachid Benhida, Lisa Kinget, Benoit Beuselinck, Cyril Ronco, Gilles Pagès, Maeva Dufies
BACKGROUND: In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. Our study explored the potential of enhancing ccRCC treatment by concurrently using CXCR2 inhibitors alongside immunotherapies. METHODS: We analyzed ELR + CXCL levels and their correlation with patient survival during immunotherapy. RCT001, a unique CXCR2 inhibitor, was examined for its mechanism of action, particularly its effects on human primary macrophages...
March 19, 2024: Journal of Experimental & Clinical Cancer Research: CR